UnitedHealth Group (UNH) - Annual Review 2025

Sell
Rating
$595
Target Price
24%
Upside

Executive Summary

UnitedHealth Group continues to demonstrate strong market resilience. Our proprietary Annual Review model indicates robust fundamentals despite macroeconomic headwinds. Key catalysts include product innovation in AI and strategic cost optimization.

Valuation Methodology

We utilize a blended approach of DCF (50%) and EV/EBITDA multiples (50%). Our WACC assumption is 8.9% based on a beta of 0.97.

Risk Factors

Generated by Office Nexus Analytical Engine | 2026-02-19